christie counteract tech

Christie CounterAct

  • 1st place

Project creator(s)

Entered into the following categories


  • First place, Covid

We need commercial UV disinfection technology that effectively reduces harmful pathogens, is safer for use in indoor spaces, and adds a layer of defense as part of a multi-disinfection strategy like regular cleaning.

Urbanization, worldwide population growth, and global travel contribute to diverse contact among people, livestock, and wildlife, increasing the frequency and transmission of new pathogens that may harm us. We need safe and effective disinfection technology that reduces pathogens now, and for the future.

Christie CounterAct™ commercial UV disinfection fixtures contain patented Care222® technology that emits filtered far-UVC 222nm light, designed to neutralize pathogens with people present while meeting established safety guidelines.

UVC light has been used effectively for more than a century to disinfect spaces including hospital operating rooms as well as devices like medical and dental tools and laboratory equipment. UVC inactivates airborne and surface pathogens like viruses and bacteria by damaging their RNA and DNA, however, conventional germicidal lamps emit longer-wavelength UVC light (>230nm) that presents a human health hazard to unprotected eyes and skin.

What’s new is the discovery and application of far-UVC 222nm light, a sweet spot on the UV spectrum that doesn’t deeply penetrate human eyes and skin, making it safer to use while people are present, while significantly reducing pathogens, including SARS-CoV2, the coronavirus that causes COVID-19, as well as harmful bacteria.

Care222 is the world’s first UVC technology with a proprietary filter that blocks potentially harmful UVC wavelengths from being emitted. Care222’s proprietary optical filter prevents longer UVC wavelengths (>230nm) that present a human health hazard from being emitted—an especially important feature that other 222nm and far-UVC-emitting products do not have.

Christie CounterAct is undergoing CE and UL certification, which is particularly important for fixtures used in occupied spaces to ensure they operate in line with current regulatory guidelines and standards with respect to exposure limits.

The far-UVC light emitted from CounterAct has demonstrated through lab testing to inactivate up to 99% of pathogens such as Escherichia coli (E. Coli) and antibiotic resistant superbugs such as Methicillin-resistant Staphylococcus aureus (MRSA) and Ushio’s testing with Care222 lamps has been shown to reduce airborne viruses like SARs-CoV-2, the virus that causes COVID-19, by over 99%.

More information can be found here.

Your web browser is out of date. Update your browser for more security, speed and the best experience on this site.

Find out how to update